UroGen Q3: ZUSDURI Reaches $68M, Net Loss Narrows to $1.5M, JELMYTO Guidance Cut to ~$90M
URGN sits 87% above its 52-week low of $16.5.
Summary
UroGen's Q3 revenue jumped to $89.0 million on $68.0 million of ZUSDURI sales, cutting the net loss to $1.5 million, but JELMYTO guidance was cut to about $90 million for 2026.
Key Events · Earnings and Guidance · URGN
-
ZUSDURI Drives Q3 Revenue to $89.0M
ZUSDURI net product revenue was $68.0 million, up 35% quarter-over-quarter, lifting total revenue to $89.0 million from $27.5 million a year earlier.
-
Net Loss Narrows to $1.5M
The quarterly net loss fell to $1.5 million, or $0.03 per share, from $33.3 million, or $0.69 per share, in Q3 2025.
-
JELMYTO Guidance Cut to ~$90M
Full-year 2026 JELMYTO revenue guidance was lowered to approximately $90 million from $97-$101 million, reflecting a ~$1.5 million CMS discard-drug true-up and competitive trial enrollment affecting patient starts; Q3 JELMYTO revenue was $21.0 million versus $25.7 million a year ago.
-
Cash of $90.5M Against $125.2M Deficit
Cash, cash equivalents and marketable securities totaled $90.5 million as of September 30, 2026, against total liabilities of $397.1 million and a shareholders' deficit of $125.2 million.
Analysis · URGN · Life Sciences
UroGen's growth story now rests almost entirely on ZUSDURI: the bladder-cancer gel did $68.0 million in the third quarter, up 35% from Q2, and total revenue of $89.0 million dwarfed last year's $27.5 million. That ramp pulled the quarterly net loss down to $1.5 million from $33.3 million a year ago, a near-breakeven quarter. Against that, the legacy JELMYTO franchise is shrinking — $21.0 million versus $25.7 million a year earlier — and management cut full-year JELMYTO guidance to about $90 million from $97-$101 million, citing a $1.5 million CMS discard-drug true-up and competitive trial enrollment pulling patients away. The balance sheet is the constraint: $90.5 million of cash against a $125.2 million shareholders' deficit and $397.1 million of total liabilities means the company still depends on ZUSDURI's continued climb. The UGN-103 NDA has a June 14, 2027 PDUFA date, and a new patent running to July 2044 extends the franchise's runway if approved.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 41.4% of the 1207 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, URGN was trading at $30.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $16.50 to $50.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.